Natriumklorid /ml, Fresenius Kabi

ApprovedSmall molecule

Natriumklorid /ml, Fresenius Kabi is one of 48 small molecule programs targeting Coronary Artery Bypass. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery BypassActive, not recruiting

Primary HyperparathyroidismActive, not recruiting

Coronary Artery BypassPhase 3

Active, not recruiting

Primary HyperparathyroidismApproved

Active, not recruiting

Competition

Competitive Landscape

148 competitors in Coronary Artery Bypass

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Phase 3

1 2

Farxiga

AstraZeneca

Phase 3

1 3

Cyklokapron

AAmring

Phase 3

3 4

Aggrastat

MMedicure

Phase 3

1 5

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

1 6

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Bactroban

PPadagis LLC

Phase 3

1 8

Glargine Insulin

AstraZeneca

Phase 3

1 9

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

1 10

Low-Dose Aspirin

PPharmaEssentia Japan K.K.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalRecruiting

Primary Hyperparathyroidism

NCT06859580

Clinical

Trials by Indication[1]

Primary Hyperparathyroidism1 trial

Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism

Recruiting·UUniversity of Aarhus·Phase 4·NCT06859580·140 enrolled

Coronary Artery Bypass1 trial

A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof

Completed·PPharmacosmos A/S·Phase 3·NCT01563367·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Natriumklorid /ml, Fresenius Kabi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Natriumklorid /ml, Fresenius Kabi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Natriumklorid /ml, Fresenius Kabi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Aarhus

Natriumklorid /ml, Fresenius Kabi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Primary Hyperparathyroidism1 trial

Coronary Artery Bypass1 trial

References

Drug Info

Quick Facts

Related News